Abstracts tagged "pharmacokinetics and tofacitinib"

Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…